Central Trust Company’s Ionis Pharmaceuticals IONS Stock Holding History

Central Trust Company’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-15	Closed	-$525	–	1477
2024 Q4	$525	Buy	+15	New	+$561	﹤0.01%	1403
2020 Q2	–	Sell	-60	Closed	-$3K	–	1102
2020 Q1	$3K	Hold	60	–	–	﹤0.01%	1033
2019 Q4	$4K	Hold	60	–	–	﹤0.01%	1075
2019 Q3	$4K	Hold	60	–	–	﹤0.01%	1060
2019 Q2	$4K	Buy	+60	New	+$4.24K	﹤0.01%	1051
2018 Q2	–	Sell	-200	Closed	-$9K	–	1288
2018 Q1	$9K	Hold	200	–	–	﹤0.01%	1006
2017 Q4	$10K	Hold	200	–	–	﹤0.01%	977
2017 Q3	$10K	Sell	200 -83	-29%	-$4.35K	﹤0.01%	950
2017 Q2	$14K	Buy	283 +83	+42%	+$3.87K	﹤0.01%	903
2017 Q1	$8K	Hold	200	–	–	﹤0.01%	995
2016 Q4	$10K	Hold	200	–	–	﹤0.01%	992
2016 Q3	$7K	Hold	200	–	–	﹤0.01%	992
2016 Q2	$5K	Hold	200	–	–	﹤0.01%	1047
2016 Q1	$8K	Hold	200	–	–	﹤0.01%	979
2015 Q4	$12K	Hold	200	–	–	﹤0.01%	944
2015 Q3	$8K	Hold	200	–	–	﹤0.01%	1016
2015 Q2	$12K	Buy	+200	New	+$12.7K	﹤0.01%	967

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Central Trust Company's IONS Position: Q1 2025 in Review

Central Trust Company sold out of Ionis Pharmaceuticals (IONS) in Q1 2025, closing a stake of 15 shares — an estimated $525 sold.

Central Trust Company first reported a position in IONS in Q2 2015 and held it in 17 quarters. The position peaked at $14K in Q2 2017. 343 funds tracked by Wall St. Rank hold IONS as of Q1 2025.

Central Trust Company reported no remaining Ionis Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Central Trust Company sold 15 Ionis Pharmaceuticals shares in Q1 2025, an estimated $525.
Central Trust Company first reported a position in Ionis Pharmaceuticals in Q2 2015 and held it in 17 quarters.
Central Trust Company's Ionis Pharmaceuticals position peaked at $14K in Q2 2017.
343 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2025.

Based on Central Trust Company's 13F filing for Q1 2025, filed 18 Apr 2025.